Swiss drug review times trail FDA and EMA, increased due to COVID


21 August 2023 - While lagging other regulators in bringing new drugs to market, Swiss regulators say their review times are comparable to the EMA and attributed recent delays in approvals to the COVID-19 pandemic.

Swissmedic published a report on 17 August comparing its drug approval times to those of the EMA and US FDA. The agency noted that while it lagged significantly behind US regulators, its review times match with those of EMA.

Read RAPS article

Michael Wonder

Posted by:

Michael Wonder